Ken Griffin Kymera Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 24,600 shares of KYMR stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,600

Previous 22,600 8.85%

Holding current value

$1.03 Million

Previous $674,000 72.7%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$30.16 - $52.4 $2.78 Million - $4.84 Million	-92,325 Reduced 60.09%	61,332 $2.9 Million
Q2 2024 Aug 14, 2024	SELL	$29.85 - $39.42 $3.22 Million - $4.25 Million	-107,724 Reduced 41.21%	153,657 $4.59 Million
Q1 2024 May 15, 2024	SELL	$22.9 - $43.57 $2.52 Million - $4.8 Million	-110,062 Reduced 29.63%	261,381 $10.5 Million
Q4 2023 Feb 14, 2024	BUY	$10.97 - $26.84 $1.67 Million - $4.09 Million	152,460 Added 69.62%	371,443 $9.46 Million
Q3 2023 Nov 14, 2023	SELL	$13.9 - $23.88 $842,326 - $1.45 Million	-60,599 Reduced 21.67%	218,983 $3.04 Million
Q2 2023 Aug 14, 2023	BUY	$22.4 - $34.92 $6.26 Million - $9.76 Million	279,364 Added 128148.62%	279,582 $6.43 Million
Q1 2023 May 15, 2023	SELL	$24.84 - $38.75 $690,328 - $1.08 Million	-27,791 Reduced 99.22%	218 $6,000
Q4 2022 Feb 14, 2023	SELL	$19.57 - $30.92 $462,047 - $730,021	-23,610 Reduced 45.74%	28,009 $699,000
Q3 2022 Nov 14, 2022	BUY	$20.91 - $34.27 $1.08 Million - $1.77 Million	51,619 New	51,619 $1.12 Million

Others Institutions Holding KYMR

# of Institutions

184

Shares Held

64.4M

Call Options Held

50.6K

Put Options Held

81.7K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.3B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account